Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [Japanese GAAP] (Consolidated)

Overview of Results

Riken Vitamin recorded interim net sales of 50,189 million yen, an increase of 6.2% compared with the same period last year. However, operating income decreased to 3,639 million yen, a decline of 11.1% year-over-year. Ordinary income was 4,209 million yen, and interim net income attributable to owners of parent was 3,192 million yen, a decrease of approximately 5% year-over-year. By segment, domestic food, domestic chemical products and overseas businesses all posted sales growth, but profits were pressured by higher raw material and labor costs and a revised estimate for asbestos removal expenses. Holdings of treasury stock increased, and the equity ratio rose to 72.6%.

Outlook and Dividend Policy

Earnings forecasts for the fiscal year ending March 2027 have been revised and a change to the dividend policy has been announced. Shares outstanding at fiscal year-end are 30,705,100 shares, treasury stock at fiscal year-end is 2,140,919 shares, and the average number of shares during the period is 28,920,719 shares. The latest dividend forecast is 118 yen for the full fiscal year ending March 2027 (interim dividend at the end of Q2: 55 yen; the full-year forecast includes a 63 yen dividend increase). Taking into account domestic and international market conditions, Riken Vitamin will monitor factors such as rising raw material costs, foreign exchange trends and asbestos removal expenses, while promoting a medium-term plan aimed at sustainable growth.